Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic rhinosinusitis with nasal polyps when compared with placebo, according to study results. In a double ...
JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...
Budesonide (micronized) 0.25mg/2mL, 0.5mg/2mL, 1mg/2mL; susp for inhalation. Pulmicort Respules is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose Respules ...
Inhaled budesonide (Pulmicort), commonly used in asthma, helped COVID-19 outpatients at extra risk for severe illness recover more quickly relative to standard care in the pragmatic PRINCIPLE trial, ...
NEW YORK (Reuters) - AstraZeneca Plc and Teva Pharmaceutical Industries Ltd said on Tuesday they have reached a settlement in their patent infringement dispute over AstraZeneca's Pulmicort Respules ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Two drugs are better than one when it comes to stopping asthma attacks in progress, a new clinical trial has found. The study, of more than 3,100 asthma patients, found that a two-drug "rescue" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback